Диссертация (1335885), страница 35
Текст из файла (страница 35)
Pract. – 2009. –15(3). – p. 202-210.232.Quante A., van Haall F., Anghelescu I. Psychopharmacologicalcombination therapy in bipolar disorder.//Forichr. Neurol. Pssychiatr. – 2009. –77(5). – p. 252-262.233.Raison C.L., Capuron L., Miller A.H. Cytokines sing the bluesinflammation and the pathogenesis of depression.//Trends Immunal.-2006.-27.-1.p.24-31.234.Rapaport M.H., Gharabawi G.M., Canuso C.M.
et al. Effects ofrisperidone augmentation in patients with treatment-resistant depression: resultsofopen-labeltreatmentfollowedbydouble-blindcontinuation.//Neuropsychopharmacology.-2006.-31.-p.2505-2513.235.Raja M., Azzoni A. Are antidepressants warranted in the treatment ofpatients who present suicide behavior?//Hum. Psychopharmacol. – 2008. – 23(8).– p. 661-668.236.Rao S., Zisook S.
Anxious depression: clinical features andtreatment.// Curr. Psychiatry. Rep. – 2009. – 11(6). – p. 429 – 436.237.Rakofsky J.J., Holtzheimer P.E., Nemeroff C.B. Emeiging targets forantidepressant therapies.// Curr. Opin. Chem. Biol. – 2009. – 13(3). – p. 291-302.238.six–Ravizza L.
Amisulpride in medium – term treatment of disthymia: amanth/double–blendsafetystudyPsychopharmacol. – 1999. – 13(3). – p. 248 – 254.versusamitriptyline.//J.186239.Raundrup A., Minkvad I, Fog R. et al. Mania, depression and braindopamine.//Jn.: Currentdevelopments in psychopharmacology. W.B.
Essman,L.Valzelli (eds.). – New York: Spectrum Press. – 1975. – 2. – p. 206 – 248.240.Reeves R.R., Mack J.E., Beddingfield J.J. Neurotoxic syndromeassociated with risperidone and fluvoxamine. //Ann Pharmacother. - 2002. - Mar.36 (3). – p. 440-443.241.Richelson E. Multi-modality: a new approach for the treatment ofmayor depressive disorder// Jnt Neuropsychopharmacol.-2013.-16.-6.-p.14331442.242.Rocca P., Marchiaro L., Rasetti R., Rivoria E., BogettoF.//Psychiatry Res. - 2002.
– Oct. 112(2). – p. 145-152. Ireland.243.Rocca P., Fonzo V., Ravizza L. et al. A comparison of paroxetineand amisulpride in the treatment of dysthymic disorder.//J. Affect. Disord. –2002. – 70. – 3. – p. 313 – 317.244.Rock P.L., Roiser I.P., Riedel W.I., Blackwell A.D. Cognitiveimpairment in depression: a systematic review and meta-analisis.// Psychol.Med.2014.-44.-p.2029-2040245.Rosa A.R., Franco C., Torrent C., Comes M., Cruz N., Horga G.,Benabarre A., Vieta E.
Ziprasidone in the treatment of affective disorders: areview. // CNS Neurosci Ther. – 2008. – Winter. – 14(4). – p.278-286.246.Rothschild A.J., Samson J.A., Bessette M.P., et al (1993) Efficacy ofthe combination of fluoxetine and perphenazine in the treatment of psychoticdepression.//Journal of Clinical Psychiatry. -1993-54.-p. 338-342.247.Sagud M., Mihaljevic-Peles A., Muck-Seler D., Jakovljevic M.,Pivac N. Quentiapine augmentation in treatment-resistant depression: anaturalistic study.// Psychopharmacol.
- 2006. - 187. - p. 511-514.248.Samer C.F., Lorenzini K.Ing, Rollason V., Daali Y., Desmeules I.A.Appication of CYP 450 Teting in the clinical setting//Mol.Diagn.ther.-2013.-17.3.-p.165-184.187249.Scarzella R., Scarzella L., Rovera G.G.Amisulpride versussulpiride: studio clinico in doppio cieco su 68 pazienti affetti da disturbodistimico.// Giornale di Neuropsicofarmacologia.-1990.- 12.-p.
73-78250.Schatzberg A.F., ColePsychopharmacology.4thJ.O., De Battista C. Manual of Clinicaled.//WashingtonD.C.AmericanPsychiatricPublisching. – Jn. – 2003. – p.42.251.Schüle C., Baghai T.C., Eser D. et al. Mirtazapine monotherapyversus combination therapy with mirtazapine and aripiprazole in depressedpatients with out psychotic features: a 4 – week open – label parallel – groupstady.//J. Biol. Psychuat. – 2007. – 8. - № 2. – p. 112 – 122.252.SeemanP.Atypicalantipsychoticsmechanismofaction.//Can.J.Psychiatry.-2002.-47(1).-27-38.253.Seo H.J., Jung Y.E., Woo Y.S., Jun T.Y., Chae J.H., Bank W.M.Effect of augmentated atypical antipsychotics on weight change in patients withmajor depressive disorder in a naturalistic setting.//Hum. Psychopharmacol.
–2009. – 24(2). – p. 135-143.254.Shajahan P., Taylor M. The uses and outcomes of quentiapine indepressive and bipolar mood disorders in clinical practice.//J. Psychopharmacol.– 2009. – 22. [Epub ahead of print].255.Shelton R.C., Williamson D.J., Corya S.A., Sanger T.M., VanCampen L.E., Case M., Briggs S.D., Tollefson G.D. Olanzapine/ FluoxetineCombination for Treatment-Resistant Depression: A Controlled Study of SSRIand Nortriptyline Resistance.//Journal of Clinical Psychiatry – 2005.– 66. – p.1289 – 1297.256.Shelton R.C., Reddy R. Adjunctive use of modafinil in bipolarpatients: just another stimulant or not?//Curr.
Psychiatry Rep.-2008.-10(6).-p.520524257.Shelton R.C., Stahl S.M. Risperidone and paroxetine given singlyand in combination for bipolar depression. // J. Clin. Psychiatry .- 2004.188258.Shelton R.C., Tollefson G.D., Tohen M. Stahl.S., Cannon K.S.,Jacobs T.G., Buras W.K., Bymaster F.P., Zhang W., Spencer K.A., FeldmanP.D., Meltzer H.V..
A novel augmentation strategy for treating resistant majordepression. //Am J. Psychiatry. – 2001. - Jan. 158 (1). – p. 131-134.259.SimonJ.S.,NemeroffC.B.Aripiprazoleaugmentationofantidepressants for the treatment of partially responding and nonrespondingpatients with major depressive disorder.//Journal of Clinical Psychiatry – 2005 –66. – p. 1216 – 1220.260.Siris S.G. Diagnosis of secondary depression in schizophrenia.Implications for DSM – 4.//Shizophr. Bull.
– 1991. – 17. – p. 75 – 98.261.Smeraldi E. Amusulpride versus fluoxetine in patients withdysthymia and major depression in partial remission : a double – blind,comparative study. // J. Affect. Disor. – 1998. -48. – p. 47 – 56.262.Smeraldi E. Haefele E., Crespi G. et al. Amusulpride versusfluoxetine in dysthymia:Preliminary resalts of a double – blind, comparativestudy.
// Eur. Psychiatry. – 1996. -v.11. –s.3. - p. 141 – 143.263.Spina E., Avenoso A., Scordo M.G., Ancione M., Madia A., GattiG., Perucca E. Inhibition of risperidone metabolism by fluoxetine in patients withschizophrenia: a clinically relevant pharmacokinetic drug interaction.//J. Clin.Psychopharmacol. - 2002. - Aug. 22 (4).
– p. 419-423.264.Spijker J., de Graf R., Bijl R.V., Beekman A.T., Ormel J., NolenW.A. Duration of major depressive episodes in the general population: resultsfromTheNetherlandsMentalHealthsurveyandIncidencestudy(NMHSIS).//Br.J.Psychiatry.-2002,-181.-p.208-213.265.Stahl Stephen M. Essential psychopharmacology. Neuroscientificbasis and practical applications.//Cambridge university press.-2000.-601.266.Standish-Barry H M A S, Bouras N, Bridges P K, Watson J P (1983)A randomized double-blind group comparative study of sulpiride andamitriptyline in affective disorder.//Psychopharmacology.-1983.- 81.- p.258–260.189267.Sümegi A.
Quetiapin in bipolar disorders.//Neuropsychopharmacol.Hung. – 2008. – 10(5). – p. 281 – 291.268.Taylor M.A., Fink M. Restoring melancholia in the classification ofmood disorders.//Journal of Affective Disorders.-2008.-105.-p.-1-14.269.Thase M.E. Evaluating atypical antipsychotics in the treatment ofrefractory depression.// J. Clin. Psychiatry. – 2009.
– 70(5). – p. 14270.Thase M.E., Entsuah A.r., Rudolph R.L. Remission rates duringtreatment with venlafaxine on selective serotonin reuptake inhibitors.//Br. J.Psychiatry. – 2001. – 178. – p. 234 – 241.271.olanzapineTohen M., Vieta E., Calabrese J.R. et al. Efficacy of olanzapine and–fluoxetinecombinationinthetreatmentofbipolardepression.//Arch.
Gen. Psychiatry. – 2003. – 60. – p. 1079 – 1088.272.Trivedi M.N. Triatvent – resistant depression: new therapies thehorizon.//Ann. Clin. Psychiatry.-2003.- 15(1).-p.59-70.273.Trivedi M.H., Corey-Lisle P.K., Guo Z., Lennox R.D., Pikalov A.,Kim E. Remission, response without remission, and nonresponse in majordepressive disorder: impact on functioning.//Jnt.
Clin. Psychopharmacol. – 2009.– 24(3) – p. 133-138.274.Trivedi M.H., Thase M.E., Fava M., Nelson C.J., Yang H., Qi Y.,Tran Q.V., Picalov A., Carlson B.X., Marcus R.N., Berman R.M. Adjunctivearipiprazole in major depressive disorder: analysis of efficacy and safety inpatients with anxious and atypical features.// J. Clin. Psychiatry. – 2008.
– 69(12).– p. 1928-1936.275.Trivedi M.H., Thase M.E., Osuntokun O., Henley D.B., Case M.,Watson S.B., Campbell G.M., Corya S.A. An integrated aaaanalysis ofolanzapine/fluoxetine combination in clinical trials of treatment – resistantdepression.// J.Clin. Psychiatry. – 2009. – 70(3). – p. 387-396.276.Tsai A.C. Unclear clinical significance of findings in adjunctivearipiprazole for major depressive disorder: comments on article by Marcus et al.//J. Clin. Psychopharmacol.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
